Total Revenue [USD, Millions]

Cost of Goods Sold (COGS) [USD, Millions]

SG&A [USD, Millions]

R&D [USD, Millions]

D&A [USD, Millions]

Interest Expense [USD, Millions]

Operating Income (EBIT) [USD, Millions]

Net Income [USD, Millions]

EPS - Basic [USD]

EPS - Diluted [USD]

bba02a9cbd247726a421640582239f48d8d0d6af02232b667c568f4441d2c973

Adjustments for Non-Cash Items [USD, Millions]

Stock-Based Compensation [USD, Millions]

Changes in Working Capital [USD, Millions]

Capital Expenditures (CapEx) [USD, Millions]

Proceeds from Debt [USD, Millions]

Repayments of Debt [USD, Millions]

Share Repurchases [USD, Millions]

Dividend Payments [USD, Millions]

Net Change in Cash [USD, Millions]

77b78e7a4da7fd68d15c7bbc5cb7a141d61f2de3e2900a7236807c295e5c436a

United States

Europe

Western Hemisphere

Western Hemisphere, excluding U.S.

Asia-Pacific, Africa

Total Revenue

3969941d4436d3029e61a5b978fb13d9bce699756c7d1f6c248b8ee335118498

1ab0679ca87b12295b5472f0cd92b17c64472c573beda00cde4e933ca8fc7fdd

Net impact of acquisitions and divestitures on worldwide operational sales growth (percentage)

Net impact of acquisitions and divestitures on Innovative Medicine segment operational sales growth (percentage)

Net impact of acquisitions and divestitures on U.S. operational sales growth (percentage)

Net impact of acquisitions and divestitures on international operational sales growth (percentage)

Net impact of acquisitions and divestitures on MedTech segment operational sales growth (percentage)

Impact of the Covid-19 Vaccine sales decline on worldwide operational sales (percentage)

Impact of the Covid-19 Vaccine sales decline on Innovative Medicine segment operational sales (percentage)

Impact of the Covid-19 Vaccine sales decline on international Innovative Medicine operational sales (percentage)

Impact of the Covid-19 Vaccine sales decline on the European region operational sales (percentage)

7e7cab8423d58ce1312f5b7d3c638d179a2e2a48ce8cac7a24c0d9523869d2a0

Sales to customers (USD, millions)

Cost of products sold (USD, millions)

Gross profit (USD, millions)

Selling, marketing and administrative expenses (USD, millions)

Research and development expense (USD, millions)

Interest expense, net of portion capitalized (USD, millions)

Other (income) expense, net (USD, millions)

Restructuring (USD, millions)

Earnings before provision for taxes on income (USD, millions)

Provision for taxes on income (USD, millions)

Net earnings (USD, millions)

4f38d36316dc17027bd7e7cdcc7936eb71526042aeade05a5c0164ce6138d652

Free Cash Flow (USD, millions)

0f6524534a4c170d80bbadbeff5a6c8b4a7e00b381e1f08ffb29b0b4de12f096

23911ed8bb1a96b08b76fbf64840c0b5021ccbace4098082bbe22e9663926a06

Cash and Cash Equivalents (USD, millions)

Total Current Assets (USD, millions)

Total Assets (USD, millions)

Total Current Liabilities (USD, millions)

Total Liabilities (USD, millions)

Total Shareholders’ Equity (USD, millions)

11341311ebc5c07b6647a36e8eea67a3e2689b02e6781ff12e52d20bdea10a43

Johnson & Johnson (JNJ)

Financials